News & Views | Published:

Tunable antibodies

Nature Biotechnologyvolume 23pages556557 (2005) | Download Citation

Subjects

A recent Keystone meeting highlighted the progress in generating effective anti-cancer antibodies by manipulating antibody binding affinity and their ability to support ADCC.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Keystone Symposium: Antibody-based Therapeutics for Cancer, Hilton Hotel, Santa Fe, New Mexico, February 17–22, 2005.

  2. 2

    Schier, R. et al. J. Mol. Biol. 263, 551–567 (1996).

  3. 3

    Colby, D.W. et al. Methods Enzymol. 388, 348–358 (2004).

  4. 4

    Weaver-Feldhaus, J.M. FEBS Lett. 564, 24–34 (2004).

  5. 5

    Weinstein, J.N. et al. Ann. NY Acad. Sci. 507, 199–210 (1987).

  6. 6

    Adams G.P. et al. Cancer Res. 61, 4750–4755 (2001).

  7. 7

    Graff, C.P. et al. Protein Eng. Des. Sel. 17, 293–304 (2004).

  8. 8

    Cartron, G. et al. Blood 99, 754–758 (2002).

  9. 9

    Weng, W.K. & Levy, R. J. Clin. Oncol. 21, 3940–3947 (2001).

Download references

Author information

Affiliations

  1. Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, 19111, PA, USA

    • Louis M Weiner
  2. Seattle Genetics Corporation, 21823 30th Drive SE, Bothell, 98021, Washington, USA

    • Paul Carter

Authors

  1. Search for Louis M Weiner in:

  2. Search for Paul Carter in:

About this article

Publication history

Issue Date

DOI

https://doi.org/10.1038/nbt0505-556

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing